Skip to content
10-Q

Quarterly Report

EVOFEM BIOSCIENCES, INC. EVFM

0001641172-25-010529

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 9, 2025 113.36M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $221K
Current Liabilities Q1 2025 · Mar 31, 2025 $70.85M
Current Liabilities Q1 2025 · Dec 31, 2024 $80.45M
Total Liabilities Q1 2025 · Mar 31, 2025 $77.68M
Total Liabilities Q1 2025 · Dec 31, 2024 $90.26M
Current Assets Q1 2025 · Mar 31, 2025 $5.87M
Current Assets Q1 2025 · Dec 31, 2024 $13.61M
Total Assets Q1 2025 · Mar 31, 2025 $12.88M
Total Assets Q1 2025 · Dec 31, 2024 $23.79M
Short Term Debt Q1 2025 · Dec 31, 2024 $135K
Shares Diluted Q1 2025 · Mar 31, 2024 31.19M sh
Capex Q1 2025 · Mar 31, 2024 $14K
Operating Cash Flow Q1 2025 · Mar 31, 2024 $123K
Stockholders Equity Q1 2025 · Mar 31, 2024 −$70.67M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$66.51M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.16
Eps Basic Q1 2025 · Mar 31, 2024 −$0.16
Sga Expense Q1 2025 · Mar 31, 2024 $2.82M
Net Income Q1 2025 · Mar 31, 2024 −$4.81M
Operating Income Q1 2025 · Mar 31, 2024 −$2.84M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $684K
Revenue Q1 2025 · Mar 31, 2024 $3.6M